Miktionsbeschwerden und Therapieerwartungen von Patienten mit benigner Prostatahyperplasie unter medikamentöser Therapie mit Risiko einer klinischen Progression: eine prospektive Studie der „Prostate and Expectations of Treatment Epidemiology Research“ (PETER) Gruppe

Weibl, Peter; Klatte, Tobias; Laurinc, Peter; Tomaskin, R.; Shariat, Shahrokh F.; Helbich, Miroslav; Fačkovcova, Danica; Bujdák, Peter

doi:10.1007/s00508-014-0668-4

Cited by 3 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men expect to be prescribed pharmacological treatments for LUTS (the single most common answer; 43%), especially if their symptoms are severe, and expect pharmacological treatments to reduce voiding symptoms [36]. Rapid symptom improvement: 4 studies reported on the proportion of patients preferring a medication with rapid symptom relief [15,22,32,33]; 62-97% preferred a treatment that provided rapid improvement in symptoms (within a few weeks to months) [15,22].…”

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

“…Efficacy: One study comparing tamsulosin and silodosin reported a preference for tamsulosin due to good efficacy in 27% (vs 13%) [30].However, 93% would stop a-blocker Stabilisation of disease: 2 forced choice studies reported that 36-38% of men preferred a treatment that stabilised symptoms and the disease [32,33]. One study reported that 76% were willing to take two medications to provide symptom relief and that 64% were willing to wait 3 mo for symptom improvement in preference for a medication that provides long-term treatment of the underlying condition [22].…”

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

“…Willingness to pay: Sexual adverse events: -For a treatment with no side effect of impotence: s418/£30-66 -For a treatment with no side effect of reduced libido: s237/£20-46 -For a treatment with no side effect of abnormal ejaculation: s163 /£17-34 Nonsexual adverse events: -For a treatment with no side effect of dizziness: s70/£17-40 -For a treatment with no side effect of headache: s93/£16 Reduced risk of surgery: -On forced choice, 24-27% prefer a treatment that reduces the risk of future surgery [19,32,33].…”

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

“…Fifteen studies reported on expectations or preferences related to pharmacological treatment [15,[17][18][19][20]22,27,28,[30][31][32][33][34]36,40]. Principal themes related to (1) efficacy of treatment, (2) effect on stabilising the underlying disease process, (3) type of adverse events, (4) prevention of complications of benign prostatic hyperplasia, and ( 5) burden/cost of treatment (Tables 3 and 5).…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms

et al. 2021

View full text Add to dashboard Cite

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

Section: Video Urodynamics Expectations Of Video Urodynamicsmentioning

confidence: 99%

Section: Pharmacological Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms

et al. 2021

View full text Add to dashboard Cite

“…However, the patients are less concerned about early symptom relief than about long-term risks. They seek disease stabilisation, would like to reduce the risk of surgery, and look for reassurance that they do not have any serious underlying condition such as prostate cancer [11,12,29,30]. Patients also fear treatment-associated side effects and might accept a delay in the onset of relief to avoid them.…”

Section: Patients' Perspectives and Preferencesmentioning

confidence: 99%

Phytotherapy Adds to the Therapeutic Armamentarium for the Treatment of Mild-To-Moderate Lower Urinary Tract Symptoms in Men

Fornara¹,

Madersbacher²,

Vahlensieck³

et al. 2019

Urol Int

View full text Add to dashboard Cite

Background: Practice guidelines hardly recommend herbal extracts for male lower urinary tract symptoms (LUTS). However, many patients are unsatisfied with first-line synthetic drugs and often prefer herbal medicines because of good tolerability. To improve the decision-making process, which should consider the patients' expectations, it is crucial to reflect on the role of phytotherapy in the treatment of LUTS. We (panel experts) reflected on current guideline recommendations and real practice across various European countries and debated the potential role of plant extracts with a focus on pumpkin seed soft extract investigated over 12 months in two randomised placebo-controlled trials. Summary: Most guidelines give no clear recommendations on phytotherapy due to the heterogeneity of clinically investigated extracts. Nevertheless, plant extracts are prescribed to patients with mild-to-moderate LUTS. Also, self-medicating patients often handle their complaints with herbal products. Many patients aim to avoid synthetic drugs for fear of sexual functional side effects and a negative impact on their quality of life. For the elderly, vasoactive comedications might be-come an issue. When taking plant extracts, patients experience an acceptable symptomatic relief similar to that achieved with synthetics but without side effects. Key Messages: In shared decision-making for purely symptomatic treatment, a low risk of side effects takes priority. We propose to consider patient preferences in the treatment of mild-to-moderate LUTS in men with a low risk of disease progression. We found a consensus that pumpkin seed soft extract adds to the therapeutic armamentarium for patients who cannot or do not want to apply synthetic drugs.

show abstract

Influence of chronic medical conditions on older patients’ willingness to deprescribe medications: a cross-sectional study

Pereira,

Veríssimo,

Ribeiro

2024

BMC Geriatr

View full text Add to dashboard Cite

Background Aging correlates with a heightened prevalence of chronic diseases, resulting in multimorbidity affecting 60% of those aged 65 or older. Multimorbidity often leads to polypharmacy, elevating the risk of potentially inappropriate medication (PIM) use and adverse health outcomes. To address these issues, deprescribing has emerged as a patient-centered approach that considers patients’ beliefs and attitudes toward medication and reduces inappropriate polypharmacy in older adults. Our study aims to investigate whether certain chronic medical conditions are associated with older patients’ willingness to deprescribe medications. Methods A cross-sectional study enrolled 192 community-dwelling individuals aged 65 or older taking at least one regular medication. Data included demographics, clinical characteristics, and responses to the Portuguese revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire. Descriptive statistics characterized participants, while multiple binary logistic regression identified associations between chronic medical conditions and willingness to deprescribe. Results Among the participants (median age: 72 years, 65.6% female), 91.6% had multimorbidity. The analysis revealed that willingness to deprescribe significantly increased with the presence of gastric disease (adjusted odds ratio [aOR] = 4.123; 95% CI 1.221, 13.915) and age (aOR = 1.121; 95% CI 1.009, 1.246). Conversely, prostatic pathology (aOR = 0.266; 95% CI 0.077, 0.916), higher scores in the rPATD appropriateness factor (aOR = 0.384; 95% CI 0.190, 0.773), and rPATD concerns about stopping factor (aOR = 0.450; 95% CI 0.229, 0.883) diminished patients’ willingness to deprescribe. Conclusions This study highlights the intricate relationship between older patients’ attitudes toward deprescribing and chronic medical conditions. We found that gastric disease was associated with an increased willingness to deprescribe medications, while prostate disease was associated with the opposite effect. Future research should explore how patients with specific diseases or groups of diseases perceive deprescribing of medications general and for specific medications, aiding in the development of targeted interventions.

show abstract

Miktionsbeschwerden und Therapieerwartungen von Patienten mit benigner Prostatahyperplasie unter medikamentöser Therapie mit Risiko einer klinischen Progression: eine prospektive Studie der „Prostate and Expectations of Treatment Epidemiology Research“ (PETER) Gruppe

Abstract: Prostate and Expectations of Treatment Epidemiology Research study highlights and reflects on patients behavior and self-perception, patients self-perception of the disease and therapeutic priorities during the 1 year of observation.

Cited by 3 publications

References 14 publications

A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms

A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms

Phytotherapy Adds to the Therapeutic Armamentarium for the Treatment of Mild-To-Moderate Lower Urinary Tract Symptoms in Men

Influence of chronic medical conditions on older patients’ willingness to deprescribe medications: a cross-sectional study

Contact Info

Product

Resources

About